Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NP-pArg-siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Parenteral
01
Overview
**NP-pArg-siRNA** is an experimental nanotherapeutic formulation consisting of a **magnetic nanoparticle (NP) coated with poly-arginine (pArg) and conjugated with small interfering RNA (siRNA)**. It is designed for efficient intracellular delivery of siRNA, enabling gene silencing in target cells. The poly-arginine surface facilitates cell membrane penetration and intracellular delivery without relying on endosomal escape, which minimizes cytotoxicity compared to PEI or polylysine-coated nanoparticles. Upon cellular internalization, the siRNA is delivered to the perinuclear region, engaging the RNA-induced silencing complex (RISC) for gene knockdown. NP-pArg-siRNA has shown effective delivery and gene silencing in brain, breast, and prostate tumor cell lines in vitro[2].
02
Targets
PARG (Poly(ADP-ribose) glycohydrolase)
Beyond the preview
Go deeper on NP-pArg-siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NP-pArg-siRNA.